It showed single-agent activity, as well as synergistic activity in combination with cisplatin, especially in advanced cancers with ATM aberrations confirming synthetically lethal interaction between ATM deficiency and ATR inhibition during the phase 1 clinical studies [101,102,103]. The gene discussed is ATR; the disease is cancer.